Abstracts Archive - Page 8 of 2616 - ACR Meeting Abstracts

Abstract Number: 114 • 2026 Pediatric Rheumatology Symposium
Incidence of Inflammatory Arthritis Before and After Inflammatory Bowel Disease Diagnosis: A Population-Based Cohort Study
Roberta A Berard¹, Ellen Kuenzig², Jessica Widdifield³, Eric Benchimol⁴, Melody Lam⁵, Vipul Jairath⁶, Sherry Rohekar⁷, Laura Targownik⁴, Melanie Watson⁸ and Eileen Crowley⁹, ¹London Health Sciences Centre, London, ON, Canada, ²Schulich- University of Western Ontario, ON, Canada, ³Sunnybrook Research Institute, Toronto, ON, Canada, ⁴University of Toronto, ON, Canada, ⁵ICES, ON, Canada, ⁶Western University, London, ON, Canada, ⁷University of Western Ontario - London, London, ON, Canada, ⁸Western University, ON, Canada, ⁹London Children's Hospital, ON, Canada
Background/Purpose: Arthropathies are a common extra-intestinal manifestation of IBD, yet population-level data on the risk of inflammatory arthritis (IA) among individuals newly diagnosed with inflammatory…
Abstract Number: 120 • 2026 Pediatric Rheumatology Symposium
Bridging Evidence and Practice: New Institutional Pathway Increases Primary Intensification Rates for Children with High-Risk Kawasaki Disease
Amritha Yellamilli¹, Elizabeth Nguyen², Brittni Kam³, Imelda Balboni⁴ and Rajdeep Pooni⁵, ¹Stanford School of Medicine, Palo Alto, CA, ²University of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA, ³Division of Pediatric Hospital Medicine, Stanford University School of Medicine, ⁴Stanford University School of Medicine, Department of Pediatric, Division of Allergy, Immunology, Rheumatology, Palo Alto, CA, ⁵Stanford University
Background/Purpose: Prior to 2024, our institution did not have a clinical pathway for management of Kawasaki disease (KD). In April 2024, a multidisciplinary team of…
Abstract Number: 024 • 2026 Pediatric Rheumatology Symposium
Therapeutic Plasma Exchange in Pediatric Autoimmune Encephalitis
Ingrid Kattan¹, PAOLA LARA HERERA², ENRIQUE FAUGIER FUENTES³, Candy Leon, MD³, Andrea Sanchez³, VIanca De Leon³ and Enrique Juarez³, ¹HOSPITAL INFANTIL DE MEXICO FEDERICO GOMEZ, Ciudad de Mxico, Mexico, ²HOSPITAL INFANTIL DE MEXICO FEDERICO GOMEZ, MEXICO CITY, Mexico, ³HOSPITAL INFANTIL DE MEXICO FEDERICO GOMEZ
Background/Purpose: Autoimmune encephalitis (AE) is a severe neuroinflammatory disorder mediated by antibodies against neuronal receptors. Therapeutic plasma exchange (TPE) can remove autoantibodies, immune complexes, and…
Abstract Number: 108 • 2026 Pediatric Rheumatology Symposium
Gender Diverse Youth Treatment Response to Amplified Musculoskeletal Pain Syndrome Rehabilitation
Michelle Swanger-Gagne¹, Danielle Scharf¹, Barbra Murante¹, Hannah Peck¹, Dylan Gawinski Stern¹ and Homaira Rahimi², ¹Golisano Children's Hospital at the University of Rochester, NY, ²University of Rochester, Rochester, NY
Background/Purpose: Recently, our center has noted a growing gender-diverse youth population with amplified musculoskeletal pain syndrome (AMPS)/Juvenile fibromyalgia (JF). Given the known disparities in access…
Abstract Number: 112 • 2026 Pediatric Rheumatology Symposium
Burden of Latent and Active TB in Pediatric TNF-Inhibitor Therapy: A Decade of Real-World Data from a Tertiary Care Centre
Neha Rajpal¹, Meghana Somashekar², manjari Agarwal³ and sujata Sawhney⁴, ¹Sir Ganga Ram Hospital, India, ²Sir Ganga Ram Hospital, ³Sir Ganga Ram Hospital, NEW DELHI, Delhi, India, ⁴Sir Ganga Ram Hospital, Sector ³⁷ noida, Uttar Pradesh, India
Background/Purpose: India carries one of the highest global burdens of tuberculosis (TB). Children on TNF inhibitor(TNFi) therapy face an increased risk of latent TB infection…
Abstract Number: 007 • 2026 Pediatric Rheumatology Symposium
Subtle Signs, Severe Consequences: Clinical profile of infants with giant coronary aneurysms compared to those with normal coronaries. A multicentric retrospective analysis of infants with Kawasaki disease
Abhay Shivpuri¹, manjari Agarwal² and sujata Sawhney³, ¹Neoclinic Children's Hospital, Jaipur, Rajasthan, India, ²Sir Ganga Ram Hospital, NEW DELHI, Delhi, India, ³Sir Ganga Ram Hospital, Sector ³⁷ noida, Uttar Pradesh, India
Background/Purpose: Kawasaki disease (KD) is a systemic medium vessel vasculitis that is predominantly a clinical diagnosis as defined by the American Heart Association (AHA). KD…
Abstract Number: 004 • 2026 Pediatric Rheumatology Symposium
Barriers and Facilitators to Teratogenicity Knowledge and Application among Adolescents and Young Adults with Rheumatic Disease
Brittany Huynh¹, Elizabeth Pfeiffer² and Stacey Tarvin³, ¹University of Alabama at Birmingham, ²Rhode Island College, ³Riley Hospital for Children at Indiana University, Indianapolis, IN
Background/Purpose: Prior studies demonstrate low levels of teratogenicity knowledge among adolescents and young adults (AYAs) with rheumatic disease. This study sought to describe barriers and…
Abstract Number: 026 • 2026 Pediatric Rheumatology Symposium
Treatment strategies for articular flares in JIA patients receiving biologic therapy
Jonatan zalcman, Yoel Levinsky, Liora Harel, Ruth Livny and gil amarilyo, Schneider Children's medical center of Israel
Background/Purpose: Biologic agents form the cornerstone of therapy for Juvenile Idiopathic Arthritis (JIA); however, the optimal management of flares that occur during ongoing treatment remains…
Abstract Number: 100 • 2026 Pediatric Rheumatology Symposium
Experience with Janus Kinase Inhibitors and Abatacept in Juvenile Dermatomyositis: A Retrospective Study from a Large Tertiary Center
Juan Torres Sanchez¹, Dawn Gist², Marietta DeGuzman¹, Sukru Aras², Duc Nguyen², MaiLan Nguyen³ and Amit Thakral⁴, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, ³Baylor College of Medicine, Austin, TX, ⁴Texas Childrens Hospital, Houston, TX
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare, chronic autoimmune myopathy characterized by muscle inflammation and distinctive skin manifestations. Although corticosteroids and conventional immunosuppressants remain the…
Abstract Number: 103 • 2026 Pediatric Rheumatology Symposium
Anifrolumab Use in Youngsters with Rheumatic Conditions: Case Series and a Review of the Evidence Base
Madison Hoenle¹, Kelly Wise² and Shoghik Akoghlanian³, ¹Nationwide Children's Pediatric Residency, Columbus, OH, ²Nationwide Children's Hospital, Hilliard, OH, ³Nationwide Childrens Hospital, Columbus, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease that poses unique diagnostic and therapeutic challenges in children, given they experience more severe…
Abstract Number: 001 • 2026 Pediatric Rheumatology Symposium
Longitudinal Cardiovascular Profiles of Youth with Childhood-onset Systemic Lupus Erythematosus
Joyce Chang¹, Gabrielle Alonzi², Michael Ferguson³, Andrea Knight⁴, Jane Newburger⁵, Pamela Weiss⁶, Mary Beth Son² and Karen Costenbader⁷, ¹Boston Children's Hospital, Newton, MA, ²Boston Children's Hospital, Boston, MA, ³Boston Children's Hospital, MA, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵Boston Childen's Hospital, Boston, MA, ⁶Childrens Hospital of Philadelphia, Philadelphia, PA, ⁷Brigham and Women's Hospital/ Harvard Medical School, BOSTON, MA
Background/Purpose: The cumulative impact of childhood-onset systemic lupus erythematosus (cSLE) on cardiovascular damage begins at disease onset. We sought to characterize longitudinal cardiovascular profiles of…
Abstract Number: 052 • 2026 Pediatric Rheumatology Symposium
Case Series: Treatment of Refractory Lung Disease in Systemic Juvenile Idiopathic Arthritis with Cyclophosphamide and Rituximab Combination Therapy
William Freeman¹, Randy Cron² and Eileen Rife³, ¹Zucker School of Medicine at Hofstra University, Bellerose, NY, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama Birmingham, Vestavia Hills, AL
Background/Purpose: Systemic juvenile idiopathic arthritis-associated lung disease (sJIA-LD) is a rare, potentially fatal complication of sJIA, often accompanied by pulmonary hypertension (PH) and macrophage activation…
Abstract Number: 109 • 2026 Pediatric Rheumatology Symposium
Tarsitis in Juvenile Idiopathic Arthritis: Clinical characteristics, imaging features, and treatment Response – A multicenter retrospective study
naiera assalia¹, Leraz Tobias², Yoel Levinsky¹, gil amarilyo¹, Yonatan Butbul Aviel², Liora Harel¹ and Mohamad Hamad Saied³, ¹Schneider Children's Medical Center of Israel, ²Rambam Medical Centre, Haifa,Israel, ³Carmel medical centre, Haifa, Israel
Background/Purpose: Tarsitis is defined as inflammation of intertarsal joints, overlying tendons, entheses and soft tissue and is often under-recognized particularly in pediatrics. Our aim is…
Abstract Number: 013 • 2026 Pediatric Rheumatology Symposium
Kikuchi-Fujimoto’s Disease in Systemic Lupus Erythematosus: Single-center Experience
Areum Shin¹, Seonyoung Kang², Doo Ri Kim², Soyeon Kim², Seulkee Lee³, Jaejoon Lee¹, Jihyun Kim³, Heeyeon Cho³, Yae-Jean Kim⁴, Hoon-Suk Cha¹ and Kangmo Ahn¹, ¹Samsung Medical Center, Seoul, ²Samsung Medical Center, Gangnam-gu, Seoul, ³Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, ⁴Samsung Medical Center, Gangnam District, Seoul
Background/Purpose: Kikuchi-Fujimoto disease (KD), also known as histiocytic necrotizing lymphadenitis, is a self-limited disease of unknown etiology. An association between KD and systemic lupus erythematosus…
Abstract Number: 076 • 2026 Pediatric Rheumatology Symposium
Understanding Etiology (CLUE) Study: Whole Genome Sequencing of Childhood-onset Systemic Lupus Erythematosus
Linda Hiraki¹, Zhaoyu Ding², JingJing Cao², Zuoming Deng³, Marianna Kaplan³ and Laura Lewandowski³, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²The Hospital for Sick Children, ON, Canada, ³NIH/NIAMS
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a potentially life-threatening autoimmune disease. Childhood-onset SLE (cSLE) patients have early disease onset and incur more organ damage than…

« Previous Page
1
…
6
7
8
9
10
…
2616
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].